HC Wainwright Has Pessimistic View of Pharvaris Q1 Earnings

Pharvaris N.V. (NASDAQ:PHVS) – Investment analysts at HC Wainwright reduced their Q1 2026 earnings per share estimates for shares of Pharvaris in a report released on Monday, April 6th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.83) for the quarter, down from their prior estimate of ($0.80). HC Wainwright currently has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Pharvaris’ Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($3.71) EPS, FY2027 earnings at ($2.91) EPS, FY2028 earnings at ($1.14) EPS and FY2029 earnings at $1.64 EPS.

Several other research analysts have also recently weighed in on PHVS. Wedbush boosted their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada lowered their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pharvaris has an average rating of “Moderate Buy” and an average target price of $42.80.

Pharvaris Trading Down 1.0%

Pharvaris stock opened at $27.56 on Wednesday. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -8.18 and a beta of -2.58. The stock has a fifty day simple moving average of $27.07 and a two-hundred day simple moving average of $25.50. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.85.

Institutional Trading of Pharvaris

A number of hedge funds have recently bought and sold shares of PHVS. GF Fund Management CO. LTD. purchased a new stake in Pharvaris during the fourth quarter valued at $35,000. JPMorgan Chase & Co. increased its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Pharvaris during the third quarter valued at $75,000. Barclays PLC purchased a new stake in Pharvaris during the fourth quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Pharvaris during the fourth quarter valued at $86,000.

Key Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $60 price target while materially raising several multi‑year earnings forecasts (notably FY2028–FY2030 and FY2029 EPS to $1.64 from $1.27), signaling stronger long‑term profitability expectations for Pharvaris. HC Wainwright analyst note
• Positive Sentiment: Wedbush raised its price target to $42 and kept an “Outperform” rating, which supports upside sentiment from another sell‑side firm and may attract momentum buyers. Benzinga note
• Neutral Sentiment: Brokerage coverage remains broadly favorable — reports show an average rating around “Moderate Buy,” reflecting mixed but generally constructive analyst views that could limit downside. Consensus rating article
• Neutral Sentiment: Analyst commentary and a recent feature examine the shift in Pharvaris’ investment narrative after Phase 3 activity and 2025 losses — useful context for investors but not a direct catalyst on its own. Yahoo Finance piece
• Negative Sentiment: HC Wainwright made small near‑term downward tweaks to Q1 and Q2 2026 EPS (e.g., Q1 to ($0.83) from ($0.80), Q2 to ($0.89) from ($0.87)), which highlight weaker near-term profitability versus prior expectations and can pressure short‑term sentiment. HC Wainwright estimates
• Negative Sentiment: Royal Bank of Canada published a pessimistic forecast for PHVS, adding downside analyst noise and potentially increasing selling pressure from cautious investors. RBC outlook

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.